Trials / Unknown
UnknownNCT03306836
Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid Operation 2
Multi-center,Single Blind,Prospective Randomized Controlled Trial of Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid Operation
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 408 (estimated)
- Sponsor
- Beijing Tiantan Hospital · Academic / Other
- Sex
- All
- Age
- 70 Years
- Healthy volunteers
- Not accepted
Summary
In the stage of randomized controlled study, our purpose is to obtain the Intraoperative anticoagulation program supported by evidence-based medicine.
Detailed description
This study is divided into anticoagulation program in cerebral aneurysm with hybrid operation and anticoagulation program in cerebral arteriovenous malformations with hybrid operation two parts, and each part divide into two stage, on the stage of registration study. This study is a multi-center, single-blind, prospective cohort study. Record the patient's intraoperative activated coagulation time Changes in detail, to observe the effect of activated coagulation time maintenance level on hemorrhage event rate of Intraoperative and postoperative 48 hours, purpose to find out the safety range of activated coagulation time level in cerebral aneurysm and arteriovenous malformations with hybrid operation. On the stage of randomized controlled study. This study is a multicenter, single-blind, prospective, randomized controlled study. Patients is divided into intraoperative standard dose group of Heparin Sodium and low dose group of Heparin Sodium randomly. To observe the effect of different anticoagulation regimens on activated coagulation time safety coverage rate during surgery, and finally develop a scientific and effective intraoperative anticoagulant therapy program.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Heparin Sodium | Infused with 5000 IU of Heparin Sodium |
| DRUG | Heparin Sodium | Infusion Heparin Sodium at a rate of 18 IU / kg.h |
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2020-09-01
- Completion
- 2021-08-01
- First posted
- 2017-10-11
- Last updated
- 2017-10-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03306836. Inclusion in this directory is not an endorsement.